A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy

NCT ID: NCT01633086

Last Updated: 2015-03-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2013-02-28

Brief Summary

This is a randomized, double-blind, placebo-controlled, 2-period crossover, 12-week trial to be conducted in 50 subjects with painful diabetic neuropathy. The objective of this trial is to assess the safety and efficacy of NO gel, a NO donor, as compared with a placebo gel, in symptom relief of subjects with painful diabetic neuropathy.

Detailed Description

Neuropathic pain is a common symptom of diabetic neuropathy, and predominantly involves the lower limbs. Current strategies for the management of painful diabetic neuropathy include improved glycemic control, use of analgesics and addition of tricyclic antidepressants and anticonvulsants. However, many patients experience unsatisfactory responses and some undesired side effects. Considerable evidence implicates impaired nitric oxide synthesis plays an important role in the pathogenesis of diabetic neuropathic pain. Several small studies have shown that topical nitroglycerin ointment has local vasodilating properties, and a previous study has demonstrated that isosorbide dinitrate in spray form as a nitric oxide donor relieved some neuropathic symptoms in patients with painful diabetic neuropathy. Based on the findings, the investigators hypothesize that nitric oxide gel could be used as an alternative pain-relieving agent for patients with resistant diabetic neuropathic pain.

Conditions

Neuropathic Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

nitric oxide gel

1. st gel: sodium nitrites

2. nd gel: maleic/ascorbic acids

Group Type: ACTIVE_COMPARATOR

nitric oxide gel

Intervention Type: DRUG

1. st gel: sodium nitrites,BID local use X 28 days

2. nd gel: maleic/ascorbic acids ,BID local use X 28 days

Placebo gel

1. st gel: phosphate-buffered saline

2. nd gel: maleic/ascorbic acids

Group Type: PLACEBO_COMPARATOR

placebo gel

Intervention Type: DRUG

placebo gel,BID local use X 28 days

Interventions

nitric oxide gel

1. st gel: sodium nitrites,BID local use X 28 days

2. nd gel: maleic/ascorbic acids ,BID local use X 28 days

Intervention Type: DRUG

placebo gel

placebo gel,BID local use X 28 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects>=30 and<=80 years of age.

2. Subjects with type 1 or type 2 diabetes mellitus with painful diabetic neuropathy.

3. Subjects without undergoing treatment for painful diabetic neuropathy or with treatment for at least 3 months but still presenting neuropathic pain prior to randomization.

4. Subjects who are healthy without any serious diseases that require hospitalization during the study period.

5. Subjects who are capable of understanding and having signed the Informed Consent Form after detailed description of the treatment procedures and potential risks and benefits.

Exclusion Criteria

1. Subjects with diagnosis of cancer and are still on active therapies.

2. Subjects with diagnosis of an active disease (e.g. hyper-or-hypothyroidism, advanced chronic renal failure, severe anemia, liver cirrhosis, active infectious disease etc.) and are still under regular treatment for this disease

3. Subjects with peripheral neuropathy caused by a known acute or chronic disease or injury

4. Subjects who are on other medications with pharmacological actions that may lead to excessive formation of nitric oxide (e.g. sublingual nitroglycerin, sildanafil etc.) or may accentuate drug effects due to excessive formation of nitric oxide.

5. Subjects with severe peripheral artery disease leading to absence of foot pulses.

6. Subjects with erratic glycemic control (HbA1c 12).

7. Subjects with an active foot ulceration or infection.

8. Subjects with any known allergic reaction to any ingredient in the 2 gel preparations.

9. Subjects who have been enrolled into any clinical study in the preceding 3 months prior to randomization.

10. Subjects with current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study result

11. Female subject of childbearing potential who is lactating or has positive urine pregnancy test at V0 or refuses to adop reliable method of contraception during the study.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

China Medical University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ching-Chu Chen, M.D.

Role: PRINCIPAL_INVESTIGATOR

China Medical University Hospital

Ching-Chu Chen, M.D

Role: STUDY_DIRECTOR

China Medical University Hospital

Locations

China Medical University Hospital

Taichung, , Taiwan

Countries

Taiwan

Other Identifiers

DMR99-IRB-273

Identifier Type: -

Identifier Source: org_study_id